SREBF2 and metabolic dysfunction-associated steatohepatitis: In brief, this study reveals that MST1 markedly reduces the accumulation of FC in the liver by activating the AMPK/SREBP2 signaling axis, thereby effectively impeding the pathological progression of NASH.